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1. Introduction 
Aldehyde dehydrogenases (ALDH) belong to the oxidoreductase family, which catalyze the 
conversion of aldehydes to their corresponding acids. As a group of NAD(P)+-dependent 
enzymes, aldehyde dehydrogenases (ALDHs) are involved in oxidation of a large number of 
aldehydes into their weak carboxylic acids (Moreb, et al., 2012). ALDH is found in every 
subcellular region such as cytosol, endoplasmic reticulum, mitochondria, and the nucleus, 
with some even found in more than one location (Marchitti, et al., 2008). 
ALDH is also found in stem cells. During early life and growth, stem cells (SCs) have a 
spectacular potential to develop into several cell types in the body. In many tissues, SCs 
behave as a kind of internal repair system, dividing essentially without limit to replenish 
other cells (Fuchs & Segre, 2000). Stem cells are distinguished from other cell types by two 
important characteristics: (1) Their unspecialized properties and renewal potencies; and (2) 
differentiation into other cell types under certain physiologic or experimental conditions 
(Discher, et al., 2009, Solis, et al., 2012). These cells are identified by their expression of a 
particular panel of surface molecules, with the presence of CD73, CD90, CD105, and the 
absence of CD14, CD34, CD45, and HLA-DR. They show no proliferative response from 
alloreactive lymphocytes because of the negligible levels of extracellular MHC class I and II 
determinants and they also have important immunomodulatory functions in all the cells 
involved in both the innate and adaptive immune responses (Nauta & Fibbe, 2007). On the 
other hand, cancer stem cell theory is supported by biological reason for aging. The theory 
postulates that cancer SCs, a small subset of tumor cells also have stem cell-like properties 
(epithelial-to-mesenchymal progression, differentiation and self-renewing capacity). ALDH 
expression has demonstrated itself to be a possibly relevant prognostic marker. For this 
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reason, the subpopulation of cancer SCs (CSCs) can present a therapeutic target for poor-
prognostic, treatment-resistant and recurrent breast cancer. Through its role in oxidizing 
retinol to RA, which is a modulator of cell proliferation, ALDH1 might have a role in early 
differentiation of SCs and stem cell proliferation (Mieog, et al., 2012). 
There are several isoforms of ALDH (ALDH1A1, ALDH1A2, ALDH1A3 and ALDH8A1) 
that play a role in RA formation by oxidation of all-trans-retinal and 9-cis-retinal in RA cell 
signaling, which has been related to the “stemness” characteristics of SCs (Marcato, et al., 
2011). ALDH1 is better as a marker of breast cancer SCs than CD44+/CD24- (Tanei, et al., 
2009). While cellular markers including CD133 have been used to identify tumor SCs, 
especially for glioblastomas (GBMs) ALDH1 was desrcribed as a marker for the 
identification of non-neoplastic SCs and tumor stem cells (TSCs) (Corti, et al., 2006, 
Ginestier, et al., 2007, Huang, et al., 2009).  
After CD133- GBMs are characterized to behave as brain TSCs(Beier, et al., 2007). ALDH1 
has also been described as a stem cell marker in various solid neoplasms including lung 
cancer (Jiang, et al., 2009), breast carcinoma (Ginestier, et al., 2007), colorectal cancer (Huang, 
et al., 2009), and GBM. ALDH1B1 and ALDH1A1 are differentially expressed in normal 
human tissues. ALDH1B1 is expressed at higher levels than ALDH1A1 in human epithelial 
cancers. ALDH1B1 was abundantly expressed in adenocarcinomas originating from the 
tissue and particularly in colonic adenocarcinoma (Chen, et al., 2011).  
ALDHbr cells can be detected with ALDEFLUOR reagent by using flow cytometry or 
fluorescent microscopy. Aldefluor assay is based on the conversion of fluorescent non-toxic 
substrate for ALDH substrate to the fluorescent reaction product. Non-toxic substrate for 
ALDH can freely diffuse into intact, viable cells. The BODIPY aminoacetaldehyde is 
converted to the fluorescent product BODIPY aminoacetate by ALDH activity. These cell 
populations, which are known as ALDH bright (ALDHbr) cells are isolated from adult 
tissues by flow sorting. ALDHbr cells were also found in various cancer tissues including 
breast, liver, colon, pancreas, prostate, lung, ovarian and acute myelogenous leukemia and 
are related to cancer chemo resistance (Siclari & Qin, 2010). 
ALDHbr population may play an important role in regenerative medicine. The regenerative 
potential of ALDHbr cells obtained from different tissues was investigated in various disease 
models such as ischemic tissue damage, hind limb model, brain damage (spinal motor 
atrophy, etc.) and pancreatitis.  
Thus, as mentioned above, ALDH is an important enzyme for cancer and stem cells. This 
chapter aims to represent the important role of aldehyde dehydrogenases in stem cells, 
cancer stem cells, therapy and regenerative medicine. 
1.1. Aldehydes 
Aldehydes are formed in various physiological processes such as catabolism of transmitters 
like GABA, serotonin, adrenaline, noradrenaline and dopamine, as well as catabolism of 
amino acids. In addition, there are more than 200 different aldehydes that are produced 
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through lipid, and aldehydic intermediates through carbohydrate metabolism. Along with 
these endogenous aldehydes, there are also exogenously present aldehydes in a variety of 
industrial processes, including the production of polyester plastics (formaldehyde, 
acetaldehyde, acrolein, etc.), polyurethane, smog, cigarette smoke or motor vehicle exhaust. 
With their malodorous properties, some dietary and aromatic aldehydes are accepted as 
additives in food and cosmetics (e.g., citral, cinnamaldehyde, benzaldehyde, and retinal), 
though many others are cytotoxic (Chen, et al., 2010). Aldehydes could interact with thiol 
compounds of some proteins, leading to structural and functional alterations of these 
molecules (Weiner, et al., 2008). In order to protect the human body from the deleterious 
effects of aldehydes in general, and myocardium and the brain in particular, a fast aldehyde 
detoxification mechanism is essential. Aldehydes are significantly reactive and possess high 
diffusion capacities in cells, thus they can easily form complexes with DNA, proteins and 
lipids, of which they can alter the function and cause their inactivation. As a result of DNA 
damage induced by these complexes, many aldehydes are classified as mutagenic or 
carcinogenic, including acetaldehyde, which is derived from ethanol consumption. Over–
consumption of ethanol has been related to liver disease and several gastrointestinal and 
upper aerodigestive cancers. Numerous other cytotoxic and reactive aldehydes have been 
shown to be linked with other types of diseases (Hofseth & Wargovich, 2007, Perluigi, et al., 
2009, Chen, et al., 2010). 
1.2. Aldehyde dehydrogenases 
Aldehyde dehydrogenases [EC 1.2.1.3; systematic name: aldehyde: NAD(P)+oxidoreductase] 
catalyze aldehyde conversion into their matching acids by NAD(P)+-dependent nearly 
irreversible reaction. In 1949, mammalian ALDH was first discovered in ox liver. After that, 
many types of ALDH were distinguished according to their physico-chemical 
characteristics, enzymological properties, subcellular localization, and tissue distribution 
(Oraldi, et al., 2011). They are involved in several cell functions such as proliferation, 
differentiation, survival as well as cellular response to oxidative stress (Jackson, et al., 2011). 
ALDHs are commonly delivered from bacteria and humans (Moreb, 2008). Based on their 
physico-chemical characteristics, subcellular localization, tissue distribution and 
enzymological properties, a number of types of ALDH have been distinguished since the 
1960s, around the time when mammalian ALDH activity was observed in ox for the first 
time. In 1985, 2 ALDH genes were cloned and characterized. Genes or cDNAs for more than 
50 animals, fungi and bacterial ALDHs in addition to protein sequences have been 
discovered (Yoshida, et al., 1998).  
The human genome contains 19 ALDH functional genes and 3 pseudogenes (Black, et al., 
2009).  At least 5 ALDH isozymes function in the mitochondria, and all the ALDH genes are 
encoded in the nucleus (Chen, et al., 2010). 
All of the ALDH gene superfamily plays an important role in the enzymic detoxification of 
endogenous and exogenous aldehydes. They are also involved in the formation of molecules 
that are important in cellular processes like RA, betaine and gamma aminobutyric acid 
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formation. Furthermore, ALDHs also have several non-enzymic functions such as binding 
to some hormones and other small molecules and decreasing the effects of ultraviolet 
irradiation in the cornea (Pappa, et al., 2003, Wymore, et al., 2004). The most important role 
of ALDHs is detoxification of aldehydes, which caused cytotoxicity, mutagenicity, 
genotoxicity, and carcinogenesis in healthy cells. Mutations in ALDH genes cause severe 
diseases including Sjögren-Larsson syndrome, pyridoxine-dependent seizures, and type II 
hyperprolinemia, and also plays a role in cancer and Alzheimer's disease (Black, et al., 2009). 
Functions of some of these ALDHs in endobiotic and xenobiotic metabolisms have been 
highly reviewed before and the distinctive metabolic pathways' influences have been 
depicted. Because of their chemical reactivity, many distinct aldehydes are pervasive in 
nature and are toxic at low levels. Hence, levels of metabolic-intermediate aldehydes should 
be cautiously regulated. The presence of several distinct ALDH families in most studied 
organisms seem to have wide fundamental tissue distribution. A wide range of allelic 
variants within the ALDH gene family have been identified, leading to heterogeneity in 
pharmacogenetic characteristics between individuals, resulting distinctive phenotypes 
including intolerance to alcohol and increased risk of ethanol-induced cancers in most cases 
(ALDH2 and ALDH1A1), Sjogren-Larson Syndrome (ALDH3A1), type II hyperprolinemia 
(ALDH4A1), 4-hydroxybutyric aciduria, mental retardation and seizures (ALDH5A1), 
developmental delay (ALDH6A1), hyperammonemia (ALDH18A1), Pyridoxine-dependent 
epilepsy (ALDH7A1), and late-onset Alzheimer’s disease (ALDH2). 
ALDH dysfunction could also be caused by drugs and environmental substances, substrate 
inhibition, as well as oxidative and metabolic stress. ALDH activity in drug resistance to 
oxazaphosphorines is one of the most vigorously studied pathways. The role of ALDH1A1 
in drug resistance has been studied first in hematopoietic progenitors and more recently in 
lung cancer (Marchitti, et al., 2008). 
2. Stem cells  
During early life and growth, SCs have a spectacular potential to develop into several cell 
types in the body. In many tissues, SCs behave as a kind of internal repair system, dividing 
essentially without limit to replenish other cells (Weissman, 2000). Stem cells are 
distinguished from other cell types by two important characteristics: First, they are 
unspecialized cells and, sometimes after long periods of inactivity, they can renew 
themselves through cell division; second, under certain physiologic or experimental 
conditions, they are naturally sensitive to their environment, responding to chemical, 
physical, and mechanical features of their matrices or substrates (Discher, et al., 2009, Solis, 
et al., 2012).  
Until recently, scientists primarily worked with two kinds of SCs from animals and 
humans: embryonic SCs and non-embryonic "somatic" or "adult" SCs (Feng, et al., 2009). 
In 1981, scientists discovered ways to derive embryonic SCs from mouse embryos. In 1998, a 
detailed study of the biology of mouse SCs led to the discovery of a method to derive SCs 
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from human embryos and grow the cells in the laboratory, and these cells are called human 
embryonic SCs.  
In 2006, genetically "reprogrammed" stem-cell-like cells were identified by using specialized 
adult cells. This new type of stem cell is called induced pluripotent SCs (iPSCs) (Krishna, et 
al., 2011). 
2.1. Cancer stem cells  
Cancer is a class of diseases characterized by unregulated cell growth(Deisboeck, et al., 
2011). Cancer initiation depends on genetic mutations in series that affects cellular 
programming. Many cancer researches have focused on the identification and 
characterization of these genetic and molecular properties of cancer cells (Balmain, et al., 
2003). Tumors are also heterogeneous cellular entities whose growth is dependent upon 
dynamic interactions among the cancer cells themselves, and between cells and the 
constantly changing microenvironment (Bissell & Radisky, 2001). That kind of interaction is 
depent on signaling through cell adhesion molecules and different cell responses to growth 
factors and other external signals. All of these interactive processes act together to control 
cell phenotypic behaviors such as proliferation, apoptosis, and migration. There are over 100 
different types of cancer, and each is classified by the type of cell that is initially affected 
(Lakshmi Prasanna & Sathish Kumar, 2011). 
According to recent statistics, cancer accounts for about 23% of the total deaths in the USA 
and is the second most common cause of death after heart disease (Jemal, et al., 2007).  
Cancer is caused by many internal and external factors. Inherited mutations, hormones, 
and immune conditions are internal factors while tobacco, diet, radiation, and infectious 
organisms are environmental/acquired factors (Kalluri & Weinberg, 2009, Nagy, et al., 
2010, Langley & Fidler, 2011, Mantel & Schmidt-Weber, 2011, Noman, et al., 2011). In 
recent years, a particular sub-population of tumor cells are said to have a critical role in 
cancer; these cells are commonly called CSCs or tumor initiating cells (TICs). In most 
cancer types, CScs have been identified. CSCs are characterised by their two important 
properties: (1) Enhanced tumorigenicity; and (2) the capacity for self-
renewal/differentiation (Bonnet & Dick, 1997, Al-Hajj, et al., 2003). Thus, isolating CSCs is 
important in analyzing their characteristics in vitro. The isolated CSC population will not 
only give rise to de novo tumors with high efficiency, but will also recapitulate the tumor 
with both CSC and non-CSC populations.  
One potential human CSC marker is the membrane antigen CD133 (Prominin) identified in 
subpopulations of cells in brain, colon and lung tumors (Singh, et al., 2004, Ricci-Vitiani, et 
al., 2007, Eramo, et al., 2008). CD133+ tumor cells are also a marker identifying lung CSCs 
(Wang, et al., 2008, Salnikov, et al., 2010). 
The expression and activity of ALDHs is determined as another potential CSC marker 
(Ginestier, et al., 2007). ALDH1 is a marker of normal and malignant human mammary SCs 
and a predictor of poor clinical outcome (Huang, et al., 2009). Aldehyde dehydrogenase 
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enzymes participate in cellular detoxification, differentiation and drug resistance through 
the oxidation of cellular aldehydes (Moreb, et al., 1996).  
The functional activity of ALDH has been widely used to identify and isolate CSCs found in 
the bone marrow (Ran, et al., 2009), breast (Ginestier, et al., 2007), lung (Ucar, et al., 2009), 
ovary (Deng, et al., 2010), colon (Huang, et al., 2009), prostate (van den Hoogen, et al., 2010), 
and pancreas (Dembinski & Krauss, 2009). 
2.2. Stem cell markers 
The derivation of SCs from adult tissues, their relative ease of isolation and enormous 
expansion potential in culture make them attractive therapeutic candidates (Prockop, et al., 
2010). These cells are identified by their expression of a particular panel of surface 
molecules, with the presence of CD73, CD90, CD105, and the absence of CD14, CD34, CD45, 
and HLA-DR. They show no proliferative response from alloreactive lymphocytes because 
of the negligible levels of extracellular MHC class I and II determinants. SCs also have 
important immunomodulatory functions in all the cells involved in both the innate and 
adaptive immune responses (Nauta & Fibbe, 2007). 
3. ALDH as a stem cell marker 
In theory, ALDH isozymes including ALDH1A, ALDH1A2, ALDH1A3, and ALDH3A1, 
which are involved in drug resistance and RA formation, are vital in protecting SCs against 
toxic endogenous and exogenous aldehydes and for SCs' ability to differentiate, 
respectively. It is unknown what ALDH isozymes are responsible for the ALDH activity 
that are used to identify stem cell progenitors. In the overlap gene profile of different stem 
cell populations, ALDH7A1, known as antiquitin, and ALDH2 were identified, 
consequently, and are worthy of further investigation. There is more about ALDH to be 
explored as a cause of its full physiological function has remained elusive. ALDH7A1 is a 
green pea 26g protein, which has function in regulation of turgor pressure, and has ≥50% 
amino acid identity with the 3 pseudogenes in the ALDH family. It also has 69% equity with 
ALDH2, but nevertheless has considerably lower affinity for acetaldehyde than ALDH2. 
However, ALDH2, which is a mitochondrial enzyme, has been widely studied mostly for its 
affilitation with ethanol metabolism. Yet, there might be an extent of confusion as to how 
ALDH2 is associated in gene profiling studies. According to the nomenclature, this enzyme 
indeed is ALDH1A, related to a series of events linked to the development of dopaminergic 
neurons through its ability to produce RA. It was reported that ALDH2 or AHD2 expression 
changes during differentiation of NIH-3T3 cells into adipocytes. These studies continue to 
focus on ALDH1A1’s role in SCs and stem cell differentiation. For hematopoietic stem cell 
progenitors, ALDH1A1 has been a thoroughly established marker for many years. Reseach 
on the role of RA in granulocyte differentiation of hematopoietic SCs discovered that 
ALDH1A1 and ALDH1B1 catalyze cellular RA synthesis and are expressed in CD34+ 
hematopoietic progenitors (Russo, et al., 2002, Luo, et al., 2007).They also showed that 
ALDH1A2 or 1A3 do not show those characteristics. For the differentiation to mature 
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granulocytes, these 2 enzymes' expressions are necessary, however their expressions are lost 
once the differentiation is complete. The in vitro disulfiram treatment in which disulfiram 
acts as an ALDH inhibitor may inhibit granulocytic differentiation. ALDH1A1 is found in 
erythrocytes and has been pointed to contribute to the aldophosphamide detoxification. A 
study that inhibited ALDH and retinoid signaling with diethylamino-benzaldehyde (DEAB) 
that reported the expansion of human HSCs probably by blocking differentiation and 
assisting self-renewal and HSC expansion (Marchitti, et al., 2008). 
The cancer stem cell theory is supported by current evidence in tumor biology, which may 
also provide a biological reason for the age-related survival difference. The theory 
demonstrates that CSCs, a small subset of tumor cells with stem cell-like properties such as 
epithelial-to-mesenchymal progression, are capable of differentiation and self-renewal, after 
which leads to formation of a heterogeneous tumor cell population. Including aldehyde 
dehydrogenase-1 (ALDH1) activity, CD44+/CD24-, CD133, and ITGA6, a wide range of 
putative breast cancer stem cell markers have been proposed. ALDH1 expression has 
especially demonstrated an assurance of a clinically relevant prognostic marker. In addition, 
the subset of CSCs is shown to be relatively insusceptible to chemo and radiotherapy by 
various studies. For this reason, the subpopulation of CSCs can present a statement and a 
therapeutic target for poor-prognostic, treatment-resistant and recurrent breast cancer. 
Through its role in oxidizing retinol to RA, which is a modulator of cell proliferation, 
ALDH1 might have a role in early differentiation of SCs and stem cell proliferation (Mieog, 
et al., 2012). 
It is possible to isolate leukemia SCs depending on the elevated ALDH activity by using the 
aldefluor assay. In patient samples, the researchers encountered a population of ALDH+ 
acute myeloid leukemia (AML) cells (Rollins-Raval, et al., 2012). In most cases, the ALDH+ 
AML cells coexpressed CD34+ (formerly determined leukemia stem cell marker), and were 
introduced considerably better than the ALDH- AML cells in immunocompromised mice. In 
the same year, ALDH+ cells from breast cancers, which had the tumorigenic and self-
renewal features of CSCs, were shown to be possibly isolated. This innovative study 
displayed the potential applicability of quantifying ALDH activity in solid tumors. ALDH 
activity would be used successfully as a CSC marker for abundant cancers including liver, 
colon, lung, bone, prostate, pancreatic, head and neck, thyroid, bladder, brain, cervical and 
melanoma in the proceeding years. With one exception of a current study for melanoma, 35 
demonstrate growing evidence recommending ALDH’s activity to be a universal CSC 
marker. Nonetheless, as amounted by the aldefluor assay in various tissues and cancers, the 
cause of ALDH activity may differ. Essentially, determination of specific ALDH isoforms 
carried out commonly in certain cancers might have prognostic suitability. Besides their 
valuable function in detoxification of aldehydes, ALDHs carry out other functions such as 
serving as binding proteins for various molecules (e.g., androgens and cholestorol), 
potentially act as antioxidants by NAD(P)H production, ultraviolet light absorption and/or 
hydroxyl radical scavenging and ester hydrolysis. 
Lastly, several isoforms (ALDH1A1, ALDH1A2, ALDH1A3 and ALDH8A1), take place via 
RA formation by oxidation of all-trans-retinal and 9-cis-retinal in RA cell signaling, which 
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has been related to the “stemness” characteristics of CSCs. Consequently, its supported by 
widening evidence that ALDH may be more than just a CSC marker and have an 
accomplishable role in CSC biology (Marcato, et al., 2011). 
3.1. ALDH family members as stem cell markers 
ALDH proteins can be found in every subcellular region such as cytosol, endoplasmic 
reticulum, mitochondria, and the nucleus, with some even found in more than one location. 
ALDH isozymes found in organelles besides cytosol carry signal or leader sequences that 
make their translocation to specific subcellular regions possible. After translocation or 
import, while nuclear and microsomal signals remain intact, mitochondrial sequences might 
be removed (causing mature proteins to be shorter). Most of the ALDHs have a large tissue 
distribution and show distinct substrate specificity (Marchitti, et al., 2008). 
3.1.1. ALDH1A1 
ALDH1A1 encodes a homotetramer that is ubiquitously distributed in the adult epithelia of 
several organs such as brain, testis, kidney, eye lens, retina, liver and lungs. ALDH1A1 takes 
its position among the three highly-conserved cytosolic isozymes (see ALDH1A2 and 
ALDH1A3), which catalyze the oxidation of the retinol metabolite, retinal (retinaldehyde), 
to RA. ALDH1A1 has great affinity for the oxidation of both all-trans-(Km < 0.1 μM) and 9-
cis-retinal. By serving as a ligand for nuclear RA receptors (RAR) and retinoid X receptors 
(RXR), RA regulates gene expression; therefore its synthesis is crucial for normal growth, 
differentiation, development and the maintenance of adult epithelia in vertebrate 
animals. In retinoid-dependent tissues (including the retina), retinal-oxidizing ALDHs have 
been shown to display differential expression patterns during organogenesis in rodents, 
reflecting that RA signaling is indeed important for embryogenesis. The in vivo function of 
ALDH1A1 in RA synthesis is proven by the fact that after retinol treatment, 
while Aldh1a1−/−mice are viable and possess normal morphology of the retina, the livers of 
Aldh1a1−/− mice have reduced RA synthesis and increased serum retinal levels. Surprisingly, 
it appeared that Aldh1a1−/− mice are protected against both diet-induced obesity and insulin 
resistance and this demonstrates that retinal might regulate the metabolic response to high-
fat diets transcriptionally, and that the ALDH1A1 could be a candidate gene for therapeutic 
targeting. Supression of ALDH1A1 in cultured hepatocytes reduces both the omega-
oxidation of free fatty acids and the production of reactive oxygen species (ROS). Liver 
ALDH1A1 levels were shown to be decreased in RXRα−/− mice, which suggests that RA 
binding is an activating factor in ALDH1A1 gene expression. The androgen receptor might 
also be included in modulation of ALDH1A1, which is recognized to be an androgen 
binding protein. RA is required for testicular development and ALDH1A1 is absent in 
genital tissues of humans with androgen receptor-negative testicular feminization. 
ALDH1A1 is significantly expressed in dopaminergic neurons that are known to require RA 
for their differentiation and development in the human brain. In these neurons, ALDH1A1 is 
under the control of Pitx3, a homeodomain transcription factor that, possibly 
through ALDH1A1 upregulation, regulates the particularization and maintenance of 
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disassociated populations of dopaminergic neurons. Decreased levels of ALDH1A1 takes 
place in dopaminergic neurons of the substantia nigra of patients with Parkinson’s disease 
(PD), as well as the ventral tegmental area in schizophrenic patients. In the central nervous 
system (CNS), monoamine oxidase (MAO) metabolizes dopamine to aldehyde, as it's 
metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), which growing evidence suggests 
might be neurotoxic, and it may lead to cell death in relation to neurological pathologies 
when accumulated. In maintaining low intraneuronal levels of DOPAL, ALDH1A1 may 
undertake a critical role by catalyzing its metabolism to 3,4-dihydroxyphenylacetic acid 
(DOPAC). Being one of 139 genes that are differentially expressed in primary human HSCs, 
and through the production of RA, ALDH1A1 has been shown to promote their 
differentiation. 
These data suggest that for the therapeutic amplification of HSCs, ALDH1A1 inhibition 
could potentially be used (Marchitti, et al., 2008, Moore, et al., 2009).  
3.1.2. ALDH1A2 
ALDH1A2 is a cytosolic homotetramer expressed in several embryonic and adult tissues 
such as brain, kidney, intestine, testis, liver, retina, lung. As ALDH1A1, ALDH1A2 also 
catalyzes the reaction in which both all-trans-retinal and 9-cis-retinal oxidize to RA. 
However, when compared with other ALDH isozymes, ALDH1A2 appears to acquire the 
highest specificity (Vmax/Km = 49 nmol·min−1·mg−1·μM−1) for all-trans-retinal. This 
characteristic may be because of an uncommon discreate loop in its active site that binds all-
trans-retinal in a unique manner. 
Taking action in several developmental processes, ALDH1A2 might be a key regulator of 
RA synthesis in developing tissues. Due to defects in early heart 
morphogenesis, Aldh1α2−/− mice die in early embryonic stages in which they seem to lack 
axial rotation, incomplete neural tube closure, reduction of the trunk region and many of the 
properties of human DiGeorge/velocardiofacial syndrome, a disorder characterized by cleft 
palate, heart abnormalities and learning disabilities. During early vascular development, 
aberrations in endothelial cell cycle progression have also been determined 
in Aldh1α2−/− embryos. Aldh1a2 has been determined as a key regulator in the development 
of many tissues including kidney, retina, lung, forebrain, pancreas, and spinal cord by 
miscellanous animal models (Marchitti, et al., 2008, El Kares, et al., 2010).  
3.1.3. ALDH1A3 
ALDH1A3 is a cytosolic homodimer that participates in RA synthesis, oxidizes both all-
trans-retinal and 9-cis-retinal (Km 0.2 μM for all-trans-retinal) to RA, and has an important 
role in embryonic development; including brain, retina, skeletal muscle, tooth buds, 
intestine, kidney, prostate, lung, liver and pancreas, it is expressed in various late-stage 
embryonic and adult rodent tissues. In humans, ALDH1A3 expression has been noted in 
stomach, salivary gland, breast, kidney and fetal nasal mucosa. Aldh1a3−/− mouse embryos 
die as a result of defects in nasal development. 
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It’s been shown that ALDH1A3 takes part in the development of the eye, nucleus 
accumbens and olfactory bulbs, the forebrain, hair follicles and the cerebral cortex. 
ALDH1A3 deficiency has been shown to play a critical role in cancer by a number of 
studies. For instance, in human breast cancer MCF-7 cells, ALDH1A3 expression is 
downregulated, whereas in cultured human colon cancer cells, ALDH1A3 is one of two 
genes that are upregulated by induction of wild type p53. In mammary tumor-susceptible 
BALB/cJ mice that are heterozygous for p53, Aldh1a3 is one of five candidate genes located 
within a region determined for its linkage to mammary tumorigenesis. In mice resistant to 
induced mammary tumors, (C57BL/6J), Aldh1a3 is one of the two upregulated 
genes. ALDH1A3 is silenced by methylation in gastric cancer cells, whereas in glioblastoma 
cells, it is triggered by the antitumor agent IL-13 cytotoxin (Marchitti, et al., 2008). 
3.1.4. ALDH2 
ALDH2 is a tetrameric enzyme expressed profusely in lungs and liver; it is also present in 
organs that obligate high mitochondrial capacity for oxidative ATP generation including 
heart and brain. Apart from that, ALDH2 is also important in the aldehydic substrate 
oxidation such as 4-HNE, acrolein, and short-chain, aromatic or polycyclic carbons. To add 
to its dehydrogenase activity, depending on the substrates, ALDH2 can function as an 
esterase and reductase. More recent attention has also been focused on ALDH2 in regards to 
its function in the biotransformation of nitroglycerin, reducing it to 1,2-glyceryl dinitrate for 
the production of nitric oxide, which is a critical vasodilator (Chen, et al., 2010).  
3.1.5. ALDH7A1 
ALDH7A1 is a homotetramer that's expressed in a large number of tissues; in rat heart, liver 
and kidney, increased levels of ALDH7A1 are noted, whereas in black seabream fish 
(sbALDH7A1), ALDH7A1 is significantly formed in the liver and the kidney, excluding the 
heart. In human fetal tissues, ALDH7A1 has been encountered at elevated levels in the 
cochlea, eye, ovary, heart and kidney. In contrast, balanced levels are detected in the liver, 
spleen, muscle, lung and brain. 
Human ALDH7A1’s primary role happens in the pipecolic acid pathway of lysine 
catabolism, in which it catalyzes the oxidation reaction of alpha-aminoadipic semialdehyde 
(AASA) (Km180 μM) to alpha-aminoadipate. ALDH7A1 mutations form the molecular basis 
for pyridoxine-dependent epilepsy (PDE), an autosomal recessive disorder characterized by 
the aggression of tenacious seizures during infancy and early childhood and are avoidable 
by daily use of high-dose pyridoxine (Vitamin B6) supplementation.  
Remarkably, ADH7A1 expression in the cochlea of the ear, the region dependent on the 
healthy upkeep of internal hydrostatic pressure, clarifies that mammalian ALDH7A1 might 
have an accomplishable function in osmotic regulation and in hearing disorders. However, 
no connection has been revealed yet, including patients with the inner-ear disorder 
Ménière's disease, which effects hearing and balance. 
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ALDH7A1 is notably and differentially expressed within the first and second meiotic stages 
of porcine oocyte development. Screening of the promoter region sbALDH7A1 has 
discovered cis-elements linked with cell cycle regulation (Marchitti, et al., 2008). 
4. ALDH in cancer and cancer stem cells 
4.1. Adenocarcinoma  
Adenocarcinoma is an epithelium cancer that is generated from glandular tissue. Epithelial 
tissue includes, but is not limited to, the surface layer of skin, glands and a variety of other 
tissues that line the cavities and organs of the body. Epithelium can be derived from the 
three germ layers ectoderm, mesoderm and endoderm during embryologic period. 
Adenocarcinoma classification depends on not only being a part of the gland, but also 
depends on having the same secretory characteristics. But, this form of carcinoma can occur 
in some higher mammals, including humans (Fauquier, et al., 2003).  
Adenocarcinomas can arise in many tissues of the body due to the ubiquitous nature of 
glands within the body. While each gland may not be secreting the same substance, as long 
as there is an exocrine function to the cell, it is considered glandular and its malignant form 
is therefore named adenocarcinoma. Endocrine gland tumors, such as a VIPoma, 
an insulinoma, a pheochromocytoma, etc. are typically not referred to as adenocarcinomas, 
but rather, are often called neuroendocrine tumors. If the glandular tissue is abnormal, but 
benign, it is called an adenoma. Benign adenomas typically do not invade other tissues and 
rarely metastasize, whereas malignant adenocarcinomas do both. Colon, urogenital (cervical 
(Tewari, et al., 2002), prostate, urachus and vagina), breast (Buchholz, 2009), esophagus, 
pancreas, stomach and throat are several examples of adenocarcinoma (Subramanian & 
Govindan, 2007).  
It is reported that ALDH expression marks pancreatic cancer stem cells. Also, they have 
mentioned that the enhanced clonogenic growth and migratory properties of ALDH-
positive pancreatic cancer cells suggest a key role in the development of metastatic disease 
that negatively affects the overall survival of patients with pancreatic adenocarcinoma 
(Rasheed, et al., 2010). 
4.2. Breast cancer 
From high-grade, absence of hormone receptor expression to positive HER2 status and the 
basal-like molecular subtype, the expression of ALDH1 is in direct relation with undesired 
tumor characteristics in breast cancer (Mieog, et al., 2012). 
Breast cancer cells with stem-cell-like properties are suggested to be responsible for 
metastatic spread. Aldehyde dehydrogenase 1 (ALDH1) and cluster of differentiation 44 
(CD44) in addition to RhoC GTPase are among the stem cell markers that are expressed by 
these cells (Chaterjee & van Golen, 2011). 
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Breast CSCs were initially isolated, established on cell surface marker with 
CD24/lowCD44 expression. More currently, ‘‘functional’’ markers depending on stem cell 
properties are investigated for their plausible applications in the breast CSCs isolation. By 
this method, applying the aldefluor assay (Stemcell Technologies), originally designed to 
isolate viable HSCs and is an enzyme-based assay that recognizes ALDH activity, 
Ginestier et al. isolated breast CSCs. The assay is thought to precisely recognize ALDH 
isoform ALDH1A1 activity degree. Besides its application as a prognostic and CSC 
marker, ALDH activity that is primarily carried out by ALDH1A3 might be functional in 
breast cancer progression. 
Expression of genes and tumor sphere formation in self-renewal and differentiation could 
be changed by adding chemical RA signaling inducers or inhibitors in breast cancer cell 
lines (Marcato, et al., 2011).  
ALDH1 could work as a marker of breast CSCs better than CD44+/CD24-. Though we could 
not maintain a conclusion that ALDH1 expression was significantly related with any 
conventional clinicopathologic attributes, nevertheless, there is a compelling relation 
between ALDH1-positive breast tumors and resistance to neoadjuvant chemotherapy, 
because of the pCR rates being obtained, which are lower in ALDH1-positive tumors (9.5%) 
than ALDH1-negative tumors (32.2%). Moreover, after neoadjuvant chemotherapy, a 
considerable increase in the proportion of ALDH1-positive tumor cells was observed. These 
results are an indication of ALDH1-positive tumor cells playing an important role in 
resistance to chemotherapy. Because of tumor cells being more tumorigenic than 
CD44+/CD24-, tumor cells of breast CSCs are thought to be richer in ALDH1-positive tumor 
cells than in CD44+/CD24- tumor cells. As a matter of course, we have shown that ALDH1-
positive, in contrast with CD44+/CD24-, is closely associated with colony formation in the 
collagen gel as well. The subset of ALDH1-positive and CD44+/CD24- tumor cells has been 
reported to contain the largest proportion of breast cancer stem cells (BCSCs); consequently, 
it is speculated to have the strongest resistantance to chemotherapy. However, in our 
current study, pCR rates in the ALDH1-positive and CD44+/CD24- high subset (20%, 2 of 
10), are not the lowest among all the subsets consisting of the ALDH1-positive and 
CD44+/CD24- low subset (0%, 0 of 11), the ALDH1-negative and CD44+/CD24- high subset 
(34.1%, 15 of 44), and the ALDH1-negative and CD44+/CD24- low subset (30.2%, 13 of 43). 
Adding CD44/CD24 status to ALDH1 status does not seem to positively improve the 
prediction of response to chemotherapy. Together, these results direct us to assume that, at 
least for the prediction of resistance to chemotherapy, ALDH1-positive tumor cells serve as 
a better marker for BCSCs than CD44+/CD24- tumor cells. Because such tumors contain a 
higher proportion of CSCs, we suppose that ALDH1- positive tumors are resistant to 
chemotherapy. However, because ALDH1 has been shown to play an important role in the 
resistance to chemotherapy in hematopoietic cells, ALDH1-positive tumor cells might be 
involved in resistance to chemotherapy, regardless of whether they are CSCs or not. In 
addition to deeper illumination of ALDH1’s function in chemotherapy resistance in breast 
cancers, obtaining a significantly specific marker for BCSCs is necessary to enlighten an 
authentic role of BCSCs’ chemotherapy resistance. 
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ALDH1-positive, in contrast to CD44+/CD24-, was tremendously related to sequential 
paclitaxel- and epirubicin-based chemotherapy resistance, and the expression of ALDH1 
increased after neoadjuvant chemotherapy, which stands for an indication of BCSCs, 
determined by ALDH1, indeed having played a significant role in chemotherapy resistance. 
This means that ALDH1-positive appears to be a better marker than CD44+/CD24- in 
identifying BCSCs, at least for the prediction of resistance to chemotherapy (Tanei, et al., 
2009). 
4.3. Lung cancer 
Each year, approximately 171,000 new cases of lung cancer are diagnosed, and 160,000 
individuals do not survive from the disease in the United States. This high incidence and 
mortality makes lung cancer one of the most common cancers and the leading cause of 
cancer death in men. Lung cancer is still the leading cause of death from malignant diseases 
worldwide in spite of the advances in surgical treatment and multimodality treatments 
(Hibi, et al., 1998). 
Cancer stem cells have attributed resistance of a smaller fraction of cells in the tumor bulk 
against chemotherapeutics. The isolation of CSCs is important for these reasons and have 
been isolated using a variety of stem cell markers and phenotypes. CD133 has recently been 
reported to identify tumor-initiating cells in non-small cell lung cancer (NSCLC). ABCG2 is 
also a stem cell marker of a variety of tissues and transporter responsible for the multidrug-
resistance phenotype. However, it was demonstrated that many cells in NSCLC and SCLC 
cell lines show tumorigenic potential, regardless of ABCG2 and CD133 expression. Recently, 
ALDH activity has been used for isolation of these kinds of cells. Normal SCs were shown to 
contain higher levels of ALDH activity than their more differentiated progeny. ALDH-
positive cells of tumors have higher proliferation rates, migration and adhesion ability, and 
metastatic potential than ALDH-negative cells. This may occur because that RA product of 
ALDHs is thought to participate in cellular differentiation and stem cell self-protection 
(Serrano, et al., 2011).   
4.4. Ovarian cancer 
Epithelial ovarian cancer is the sixth most common cancer in women worldwide and it is 
still the most lethal gynecologic malignancy (Iorio, et al., 2007). Application of new 
technologies for detection of ovarian cancer could have an important effect on public health, 
but to achieve this goal, specific and sensitive molecular markers are essential (Petricoin, et 
al., 2002). Aldehyde dehydrogenase-1A1 (ALDH1A1) has been a valid marker among 
several malignant and non-malignant tissues in spite of several stem cell markers to identify 
CSCs. ALDH plays a role in the biology of TICs as well as being a stem cell marker. Because 
ALDH1A1 is implicated in chemo resistance pathways, it is questioned that targeting 
ALDH1A1 can effect cells resistant to chemotherapy and represent a potential target for 
cancer stem-cell-directed therapy. In a study, ALDH1A1 was investigated in ovarian cancer 
cell lines and patient samples and examined whether targeting ALDH1A1 sensitizes cells to 
 
Dehydrogenases 16 
chemotherapy in both in vitro and in vivo ovarian cancer models. They showed that 
ALDH1A1 expression and activity have increased chemo resistant ovarian cancer cell lines. 
Most importantly, down-regulation of ALDH1A1 expression has sensitized normally chemo 
resistant tumors to both docetaxel and cisplatin in vitro and in mouse models. Besides being 
a stem cell marker, ALDH1A1 is also a viable target for therapy and a mediator of the 
aggressive phenotype (Landen, et al., 2010). 
4.5. Pancreatic cancer 
Pancreatic adenocarcinoma is a highly lethal disease, which is usually diagnosed in an 
advanced state, and for which there is little or no effective therapies (Li, et al., 2007). Therefore, 
finding markers to detect a malignant cell transformation at an early stage is very important. 
Researches demonstrated that the pancreas possesses ALDH activity, and ALDH is also 
present in the pancreatic cancer cells. Different from other cancer tissues (such as ovarian and 
lung cancer), the activity of ALDH does not differ in pancreatic carcinoma tissue compared to 
normal pancreatic tissue. Additionally, serum levels of ALDH were not significantly elevated 
in patients with pancreatic cancer in comparison to healthy controls (Jelski, et al., 2011). 
4.6. Prostate cancer 
The latest estimates of global cancer incidence show that prostate cancer has become the 
third most common cancer in men, with half a million new cases each year, constituting 
almost 10% of all cancers in men (Quinn & Babb, 2002). Identifying the origin of cells in 
prostate cancer and its distant metastases may be important for the improvement of more 
effective treatment strategies and preventive therapies. Measurement of ALDH activity 
provides great contribution to functional identification and characterization of normal SCs 
and their malignant counterparts. ALDH activity is important for drug resistance, cell 
proliferation, differentiation, and response to oxidative stress of prostate cancer like other 
important cancers.  
ALDH enzyme activity is used for the isolation of “stem-like” cells based on a developmentally 
conserved stem/progenitor cell function. In a study, high ALDH activity was used to isolate 
human prostate cancer cells with significantly enhanced clonogenic and migratory properties 
both in vitro and in vivo. Similar to other cancer tissues, the percentage of ALDHhi cells in 
prostate cancer cell lines are also related to tumorigenicity and metastatic behavior.  
Although high expression of ALDH7A1 is shown in prostate cancer cell lines, primary 
cultures, and in primary prostate cancer tissue and matched bone metastases, ALDH3A2 
and ALDH18A1 are not observed high ALDH activity in human prostate cancer (van den 
Hoogen, et al., 2010).  
4.7. Brain cancer 
Glioblastoma (GBM) is the most common primary brain tumor in adults with an 
approximately 15-month survival (Stupp, et al., 2005). Although there are several studies to 
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improve the postoperative therapeutic applications within the last few years, there is not 
enough succes for this highly aggressive tumor. After resection, radiation, and 
chemotherapy regimens, relapses occur regularly. Thus, it is thought that this can be a clue 
to the presence of tumor stem cells (TSCs). This cellular subfraction within GBM causes 
continuous tumor growth and resistance to drugs and radiation (Rasper, et al., 2010). TSCs 
are believed to nestle in the tumor, keeping it alive and growing, providing pluripotency, 
self-renewal, and resistance to chemo and radiation therapy(Reya, et al., 2001). The first 
malignancies from which cells could be isolated and showed the potential to self-renew and 
to drive tumor formation and growth were leukemias (Bonnet & Dick, 1997). After that, a 
stem cell subfraction was described in brain tumors (Singh, et al., 2003). This was the first 
study that identified and showed a population with stem cell properties in pediatric solid 
brain tumors. Those cells were identified by their ability to proliferate under serum-free cell 
culture conditions and by the expression of CD133 and nestin. CD133 has long remained the 
most important TSC marker in malignant glioma. On the other hand, ALDH1 is a 
cytoplasmatic stem cell marker in a variety of malignant tumors and catalyzes the oxidation 
of intracellular aldehydes including the transformation of retinol to RA. As mentioned 
above, RA is a modulator of cell proliferation and differentiation that possibly contributes to 
the maintenance of an undifferentiated stem cell phenotype. Jones et al. presented a method 
to isolate human cells via flow cytometry depending on the amount of cytosolic ALDH 
(Jones, et al., 1995). Recently, Ginestier et al. found ALDH1 to be a stem cell marker in breast 
carcinoma associated with poor clinical outcomes (Ginestier, et al., 2007). Since then, ALDH1 
has been described as a marker of stemness in other solid malignancies including lung 
cancer (Jiang, et al., 2009) and colorectal cancer (Huang, et al., 2009).  
Therefore, identification and isolation of these cells seem crucial for a better understanding 
of tumor behavior, origin, and therapy. Recently, ALDH1 has been described as a marker for 
the identification of non-neoplastic SCs and TSCs (Ginestier, et al., 2007).  
So far, cellular markers including CD133 have been used to identify TSCs in GBMs, but 
recently, CD133-negative GBMs are characterized to behave as brain TSCs (Beier, et al., 2007).  
Therefore, ALDH1 has also been described as a stem cell marker in various solid neoplasms 
including lung cancer (Jiang, et al., 2009), breast carcinoma (Ginestier, et al., 2007), and 
colorectal cancer (Huang, et al., 2009) and GBM (Rasper, et al., 2010).  
4.8. Colon cancer 
Most colon cancers are adenocarcinomas that release mucus and other cellular secretions. In 
the United States in 2012, estimated new cases and deaths from colon and rectal cancer are 
reported as: 103,170 colon cancers and 51,690 deaths (Levin, et al., 2008). Studies showed that 
ALDH1B1 and ALDH1A1 are differentially expressed in normal human tissues, but 
ALDH1B1 is expressed at higher levels than ALDH1A1 in human epithelial cancers. 
ALDH1B1 was abundantly expressed in adenocarcinomas originating from the tissue and 
particularly in colonic adenocarcinoma (Chen, et al., 2011). Thus it can be deduced that 
ALDH1B1 may be a marker for colon cancer diagnosis. 
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5. Aldefluor activity in stem cells and cancer stem cells 
ALDHbr (ALDH-bright) cells can be detected with ALDEFLUOR reagent by using flow 
cytometry or fluorescent microscopy. These ALDHbr cell populations are isolated from adult 
tissues by flow sorting.  
ALDH activity was shown in human and mouse bone marrow hematopoietic progenitor cells 
(HPCs) by Jones et al. for the first time (Jones, et al., 1995). ALDH was assayed by using a new 
substrate with low light scatter properties with flow cytometry. Now this method was 
improved and known as Aldefluor assay. Aldefluor assay can be used for to measure ALDH 
activity of adult tissue cells, primary cancer cells and cultured cells. Aldefluor assay is based 
on the conversion of fluorescent non-toxic substrate for ALDH substrate to the fluorescent 
reaction product. Non-toxic substrate for ALDH freely diffuses into intact and viable cells. The 
BODIPY aminoacetaldehyde is converted to the fluorescent product BODIPY aminoacetate by 
ALDH activity (Figure 1). In this assay, a specific inhibitor of this reaction 
(diethylaminobenzaldehyde-DEAB) is used to control for background fluorescence. Aldehyde 
dehydrogenase plays a role as a cancer stem cell marker comes down to the specific isoform. 
Stem and progenitor cells are identified as cells with low side scatter and high expression of 
ALDH. DEAB allows to distinguish between ALDH-bright cells and cells with low ALDH 
activity. Generally, 105-106 cells are suspended in Aldefluor assay buffer containing BODIPY 
aminoacetaldehyde with/without DEAB. Aldefluor was excited at 488 nm and fluorescence 
emission was detected at 530/30 (van den Hoogen, et al., 2010). This assay provides a 
successful isolation of viable HSCs and more recently ALDH positive CSCs. However, 
aldefluor assay detects the ALDH activity of several ALDH isoforms expressed in the cells. 
ALDH1A1 is not the only isoform responsible from aldeflour activity. In some studies, it 
was demonstrated that ALDH1A1-deficient hematopoietic cells showed aldefluor activity 
owing to ALDH2, ALDH3A1 and ALDH9A1 isoforms (Marcato, et al., 2011). 
6. ALDH bright (ALDHbr) cell 
Intracellular ALDH enzymes are responsible for oxidizing aldehydes to carboxylic acids in 
the cell. ALDHbr cells from different tissues express high ALDH activity and have 
progenitor cell activity (Gentry, et al., 2007). Firstly, HSC were defined as SSCloALDHbr – 
reflecting their low orthogonal light scattering and bright fluorescence intensity by using 
flow cytometry (Lioznov, et al., 2005). After that, high levels of the enzyme ALDH (ALDHbr) 
have proven to be a novel marker for the identification and isolation of SCs (Mitchell, et al., 
2006). In the same time angiogenic activity of ALDHbr cells were discovered and these cells 
were used for regenerative medicine with preclinical models and have been used safely to 
treat patients in early clinical trials (White, et al., 2011).  
ALDHbr cells were found in various cancer tissues including breast, liver, colon, and acute 
myelogenous leukemia and related with cancer chemo resistance. Human and murine HSCs 
and neural stem and progenitor cells have increased ALDH activity compared to non-stem-
cells (Siclari & Qin, 2010). 
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Therefore, recently the importance of ALDH activity in normal and malignant stem cell 
functions, and the potential diagnostic and therapeutic implications gain importance 
(Moreb, 2008). 
 
Figure 1. The Aldefluor® Assay. Firstly, ALDH positive cell will uptake BODIPY-aminoacetaldehyde 
by passive diffusion and then convert BODIPY-aminoacetaldehyde into BODIPY-aminoacetate. Then 
BAA is retained inside cells, causing the subset of ALDHhi cells to become highly fluorescent (Marcato, 
et al., 2011). 
7. Aldehyde dehydrogenase in regenerative medicine 
Until today, studies showed that BM ALDHbr populations may be useful in several cell 
therapy applications (Gentry, et al., 2007). According to this information, ALDHbr population 
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may play an important role in regenerative medicine owing to RAs ALDH product (Balber, 
2011). Retinoic acids could influence tissue repair by binding to transcription factors and 
regulating developmental programs, especially ALDH1A1 and ALDH3A1 of enzyme 
isoforms that produce RAs from oxidize retinaldehyde (Moreb, 2008). Therefore, ALDH1a1 
and ALDH1A3 may influence cell activity and proliferation by controlling intracellular 
retinoid concentrations and play important roles in stem cell biology (Balber, 2011). 
The studies about value of ALDHbr cells in regenerative medicine were conducted by 
different researchers. The regenerative potential of ALDHbr cells obtained from different 
tissues were investigated in various disease models such as ischemic tissue damage hind 
limb model, brain damage and pancreatitis (Balber, 2011).  
In the beginning of studies, ALDHbr cells were obtained from bone marrow and umbilical 
cord blood and normal peripheral blood (Sondergaard, et al., 2010). Multipotent 
mesenchymal progenitors and endothelial progenitor cells are concentrated in human 
ALDHbr populations. Because of potential progenitor and paracrine activities of ALDHbr 
cells, these cells especially obtained from bone marrow are important for tissue repair. 
Manipulation of the graft to selectively concentrate or expand hematopoietic and/or neural 
stem cells prior to transplant may be a potential strategy in the future. UCBT using ALDH 
bright cells from the CB units have shown faster and higher engraftment in preliminary 
study and is being explored further (Prasad & Kurtzberg, 2010). One of these studies 
showed that human cord blood progenitors with high ALDH activity improve vascular 
density in a model of acute myocardial infarction. In this study, ALDHbr cells were homed 
to the infracted anterior surface of the heart, while ALDH-low cells were in the spleen after 
intravenously administration.   
Another study with animal model of hindlimb ischemia demonstrated that the isolated 
ALDHbr cells effectively restored blood flow to ischemic areas by mediation of local 
formation of new blood vessels with largeer diameter and increasing capillary density even 
if there was no improvement in cardiac functions (Keller, 2009).  
The reason for the restoration of tissue perfusion by ALDHbr cells were attempted to be 
explained with angiogenic properties of these cell groups. Angiogenic factors secreted by 
transplanted ALDHbr cells stimulate formation of new blood vessels at sites of ischemic 
injury (human cord blood progenitors with high ALDH activity improve vascular density in 
a model of acute myocardial infarction). Paracrine mechanisms of ALDHbr cells can protect 
endothelial cells from ischemic damage and respond to ischemic tissue damage (Balber, 
2011, White, et al., 2011).  
Another exciting finding is that ALDHbr cells improve formation of new vessels and increase 
capillary density, while ALDHbr cells together with ALDH-low cells did not restore tissue 
perfusion at all. It is suggested that ALDH-low cells can inhibit the homing and/or 
angiogenic activity of ALDHbr cells. This situation showed the importance of isolating 
ALDHbr cells from bone marrow tissue for therapeutic uses (Balber, 2011). As a result, 
ALDHbr cells may be promising for patients with ischemic heart failure and critical limb 
ischemia (Keller, 2009).   
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TISSUE OBTAINED FROM BENEFITS
 
 
Neural Tissue 
Rat embryonic neural tube 
Fetal mouse brain 
Subventricular and 
subcortical zones of adult 
mouse brain 
Ability to form neurospheres and retained 
multipotency 
Transplantation significantly ameliorated 
disease progression and extended life, but did 
not rescue the animals. 
 
Skeletal 
Muscle 
Biopsies or primary 
explants of human skeletal 
muscle 
Strong myogenic potential 
on IM transplantation 
 
Mammary 
Epithelium 
Mammary epithelium Myoepithelial, luminal epithelial and mixed 
colonies, and ducts, when transplanted into 
mammary fat pads. 
 
 
Pancreatic 
Cells 
Central acinar/terminal duct 
cells from peripheral 
acinar duct units of adult 
mice 
Contributed to both exocrine 
and endocrine lineages in the developing 
pancreas 
 
 
Prostate 
Epithelium 
 
- 
Express basal epithelial and characteristic 
prostate progenitor 
cell markers  
Corneal 
Limbic Cells 
Cadaveric 
human limbic tissue 
Protects the cornea 
from oxidative damage 
Table 1. Different tissue repair models including human ALDHbr cells (Balber, 2011). 
8. Conclusion 
Since ALDH enzyme has been proven to possess a vital role in somatic cells and their 
deficiency cause various diseases, research has focused on the presence and functions of the 
enzyme in SCs. It was demonstrated that ALDH is an important marker for identification of 
SCs and has several functions in these cells just as they possess in somatic cells.  
Exploring some of the isoforms of ALDH for use as a marker of CSCs improved the 
importance of ALDH. Thus, there are several methods to detect ALDHs and their levels 
(Marcato, et al., 2011). After the discovery of ALDH activity in human and mouse bone 
marrow hematopoietic progenitor cells (HPCs) by Jones et al. (Jones, et al., 1995), the 
properties and locations of ALDH-positive cells have started to be investigated.  
Recently, ALDHbr cells were found in cancer tissues including breast, liver, colon, and acute 
myelogenous leukemia. It was demonstrated that proliferation rates, migration and 
adhesion ability, and metastatic potential of ALDHbr CSCs were more than ALDH low cells 
and ALDHbr cells related with cancer chemo resistance. ALDHbr cells became one of new 
therapeutic target against cancer and anti-cancer studies based on targeting ALDHbr cells 
have started recently (Serrano, et al., 2011). It is expected that the anti-cancer studies with 
this perspective may intensively continue.  
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On the other hand, studies showed that BM ALDHbr populations may be useful in several 
cell therapy applications (Gentry, et al., 2007). It is suggested that ALDHbr population may 
play an important role in regenerative medicine owing to Ras, which are one of the ALDH 
products. Paracrine effects of products of ALDH activity may influence tissue repair by 
binding to transcription factors and regulating developmental programs (Balber, 2011).  
Therefore, regenerative potential of ALDHbr SCs were investigated in various disease 
models such as ischemic tissue damage hind limb model, brain damage and pancreatitis 
(Balber, 2011).  
Studies on ALDHbr cells provide restoration of tissue perfusion and stimulation of formation 
of new blood vessels in ischemic tissue damage (Keller, 2009). These promising findings 
showed that ALDHbr cells may gain importance in different areas; however, there are still 
many things to investigate about potential properties of ALDHbr cells for use in regenerative 
medicine. Thus, ALDH have many roles such as a marker of many disease and cell lines for 
detection of them also can using for therapy and have potential for use in regenerative 
medicine. 
However, there are few studies about ALDH as a marker of SCs and potential usage in 
regenerative medicine. Therefore, we suggested that studies should focus on this and this 
review aims to consider the roles of ALDH in SCs and their potential use in regenerative 
medicine. We believe that constructing a review including current studies related to this 
subject will guide future studies. 
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